Bangkok Dusit Medical Services Launches CAR-T Therapy Pilot in 2027
Bangkok Dusit Medical Services Public Company Limited plans to launch CAR-T cell therapy across four affiliated hospitals in 2027. The estimated drug cost for the treatment component is approximately 3.5 million baht. This significant medical development involves collaboration between Bangkok Dusit Medical Services Public Company Limited, Genuphtic Bio Co. Ltd., and Siam Bioscience Group. The four hospitals slated for the pilot program include Bangkok Cancer Hospital, Wattanosit Hospital, Samitivej Sukhumvit Hospital, and Samitivej Children's International Hospital. Bangkok Phuket Hospital is also included in the planned rollout. Bangkok Dusit Medical Services Public Company Limited aims to treat at least 50 patients within its network in 2027. The therapy targets hematological malignancies, specifically relapsed or refractory leukemia patients. The treatment involves genetically modifying a patient's own T-cells to target cancer cells. The process requires approval from the Department of Health Service Support and the Medical Council to ensure patient safety and regulatory compliance. The project aims to reduce treatment costs from nearly 20 million baht abroad to approximately 3.5 million baht domestically. The development of this advanced technology involved over 30 years of dedicated research by Thai scientists. The research began with Thai scientists studying abroad and collaborating with Ramathibodi Medical Sciences and Mahidol University. media reports state that the Thai healthcare sector is the first in Asia to achieve this level of integrated research, production, and treatment capability. media reports state that the initial patent and successful treatment of pediatric cancer patients occurred 10 years ago. media reports state that the production facility has the capacity to support at least 500 patients per year.
Treatment Targets Hematological Malignancies
The CAR-T cell therapy targets hematological malignancies, specifically relapsed or refractory leukemia patients. This advanced cancer treatment involves genetically modifying a patient's own immune cells to target and destroy cancer cells. This cost reduction represents a substantial financial benefit for patients receiving this life-saving therapy. The therapy development represents a major milestone in domestic cancer care capabilities within the region.
Research Development Timeline
Suradet Hong-ing, a pediatrician specializing in hematology and pediatric oncology at Samitivej Children's International Hospital, noted that he began research in this field abroad nearly 30 years ago and developed it with the Ramathibodi team. Kongkiat Ketsaphet, Executive Director and Chairman of the Executive Committee of Group 6 BDMS, stated that the goal of establishing a domestic production factory is to reduce imports and improve access to treatment for Thai people.
Glossary
- baht — The banknotes of the Thai baht are part of the physical form of the Thai baht. The issuance of the baht banknotes is managed by the Bank of Thailand. The circulating banknotes today in Thailand are ranged from 20 baht, 50 baht, 100 baht, 500 baht and 1000 baht.
- CAR-T cell therapy — Adoptive cell transfer of autologous T-cells modified with chimeric antigen receptors (CAR-T cell therapy) also causes CRS. Serum samples of patients with CAR-T associated CRS have elevated levels of IL-6, IFN-γ, IL-8 (CXCL8), IL-10, GM-CSF, MIP-1α/β, MCP-1 (CCL2), CXCL9, and CXCL10 (IP-10). The most predictive biomarkers 36h after CAR-T infusion of CRS are a fever ≥38.9 °C (102 °F) and elevated levels of MCP-1 in serum.
- hematological malignancies — MRD assessment is increasingly used, particularly in hematological malignancies like leukemia and multiple myeloma, as a powerful prognostic marker and to help guide treatment decisions. MRD was originally described in hematological cancers such as adult acute myeloid leukemia. Subsequently, MRD research has broadened out to other hematological malignancies such as multiple myeloma, as well as to solid tumors.
- Department of Health Service Support — Office of the Minister Office of the Permanent Secretary Department of Mental Health Department of Disease Control Department of Health Department of Medical Services Department of Medical Sciences Department of Health Service Support (HSS) Department of Thai Traditional and Alternative Medicine Food and Drug Administration. This department is listed among several other government departments.
- Medical Council — As a result of medical ethics complaints following Thaksin's transfer, an ad hoc subcommittee of the Medical Council of Thailand was formed and headed emeritus professor Amorn Leelarasamee. The committee began its investigation in December 2024, and received information from the PGH and Department of Corrections Hospital when investigating four doctors. The investigation found that there was a lack of conclusive evidence to validate that Thaksin was in a critical condition.
This article was written with AI assistance from multiple news reports and is reviewed by our editors under our editorial principles. Editorial Standards · Tips & Contact
Comments 0